Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of …
TARDIS Trial Investigators - International Journal of Stroke, 2015 - journals.sagepub.com
Rationale The risk of recurrence following a stroke or transient ischemic attack is high,
especially immediately after the event. Hypothesis Because two antiplatelet agents are …
especially immediately after the event. Hypothesis Because two antiplatelet agents are …
Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
MS Dzeshka, GYH Lip - Trends in cardiovascular medicine, 2015 - Elsevier
Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and
oral anticoagulation therefore is the essential part of AF management to reduce the risk of …
oral anticoagulation therefore is the essential part of AF management to reduce the risk of …
[HTML][HTML] Outcomes of non-vitamin K oral anticoagulants for secondary prevention in ischemic stroke with atrial fibrillation
Previous studies have rarely investigated the role of non-vitamin K oral anticoagulants
(NOAC) and warfarin in the secondary prevention of ischemic stroke patients with …
(NOAC) and warfarin in the secondary prevention of ischemic stroke patients with …
[HTML][HTML] Mobile health-technology integrated care in secondary prevention atrial fibrillation patients: a post-hoc analysis from the mAFA-II randomized clinical trial
AF patients with history of thromboembolic events are at higher risk of thromboembolic
recurrences, despite appropriate antithrombotic treatment. We aimed to evaluate the effect of …
recurrences, despite appropriate antithrombotic treatment. We aimed to evaluate the effect of …
Real-world direct comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Medicare beneficiaries with atrial fibrillation
It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …
Impact of previous stroke on clinical outcome in elderly patients with nonvalvular atrial fibrillation: ANAFIE registry
T Yoshimoto, K Toyoda, M Ihara, H Inoue, T Yamashita… - Stroke, 2022 - Am Heart Assoc
Background: We determined the long-term event incidence among elderly patients with
nonvalvular atrial fibrillation in terms of history of stroke/transient ischemic attack (TIA) and …
nonvalvular atrial fibrillation in terms of history of stroke/transient ischemic attack (TIA) and …
[HTML][HTML] Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum beta-lactamase-producing organisms: a …
C Ho, A Lau, K Cimon, K Farrah… - CADTH technology …, 2013 - ncbi.nlm.nih.gov
Bacterial resistance to antibiotics is an increasing problem in Canada and worldwide. 1-4
Vancomycin-resistant enterococci (VRE) are strains of Enterococcus faecium or …
Vancomycin-resistant enterococci (VRE) are strains of Enterococcus faecium or …
[HTML][HTML] Кардиоэмболический инсульт
ИВ Дамулин, ДА Андреев… - Неврология …, 2015 - cyberleninka.ru
Рассматриваются основные причины, патогенетические, клинические и
терапевтические аспекты кардиэмболического инсульта (КЭИ). Подчеркивается, что …
терапевтические аспекты кардиэмболического инсульта (КЭИ). Подчеркивается, что …
Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients
Background: Although widely used in clinical fields, real-world data on the role of warfarin
and non-vitamin K oral anticoagulants (NOACs) for the secondary prevention of …
and non-vitamin K oral anticoagulants (NOACs) for the secondary prevention of …
Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
JD Miller, X Ye, GM Lenhart, AM Farr… - ClinicoEconomics …, 2016 - Taylor & Francis
Background Understanding the value of new anticoagulation therapies compared with
existing therapies is of paramount importance in today's cost-conscious and efficiency …
existing therapies is of paramount importance in today's cost-conscious and efficiency …